Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance

Cytokinetics IncTrade
Vanguard S&P 500 Growth Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Vanguard S&P 500 Growth Index Fund ETF trades at $83.18. Which is the better fit depends on your goals.

CYTKVOOG
Market Cap
$11.12B
Sector
TechnologyBroad Market / Factor
52-Week High
$87.26$85.11
52-Week Low
$33.23$65.32
Enterprise Value
$11.59B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.

Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.

Vanguard S&P 500 Growth Index Fund ETF

VOOG (Vanguard S&P 500 Growth ETF) trades at $82.02, down 1.55% on the day, with a bullish technical signal from moving averages. The ETF recently completed a 1:6 stock split on April 21, 2026, making shares more accessible. Technical indicators show neutral oscillators but bullish moving average alignment, with support clustered around $82.

The ETF's outlook remains positive given its focus on S&P 500 growth stocks and low 0.07% expense ratio. Key risks include technology sector concentration and market volatility. Recent financial media coverage highlights VOOG's strong long-term performance potential compared to peer growth ETFs.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Vanguard S&P 500 Growth Index Fund ETF

VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.

Read more on VOOG